

Disclosure of Relevant Financial or Non-financial/Strategic Business Relationships or Partnerships

23rd Annual Meeting – The Online Experience

The Society is charged with ensuring its CME activities are balanced, independent, objective, and scientifically rigorous, through, but not limited to, by identifying and mitigating relevant financial relationships or non-financial/strategic business relationships or partnerships (relationships) between individuals in control of educational content and ineligible companies. By identifying and mitigating relevant relationships, we work together to create a protected space to learn, teach, and engage in scientific discourse free from influence from individuals that may have an incentive to insert commercial bias into a CME activity.

As a CME provider accredited by the [Accreditation Council for Continuing Medical Education \(ACCME\)](#), the ASBrS requires individuals in a position to control the educational content of a CME activity (including but not limited to, course/program chairs, moderators, faculty, authors, content reviewers, editors, planning committees, and ASBrS staff) to disclose all financial and non-financial/strategic business relationships or partnerships (relationships) with ACCME-defined ineligible company, within the 24 months prior to their involvement with the CME activity.

Individuals must review and adhere to the ASBrS CME Activity Policy and Disclosure Process as well as complete the applicable ASBrS Disclosure Form at the time they are invited to participate in a CME activity. Participation is not confirmed without the completion of the disclosure form and will be contingent upon mitigation, if necessary.

Owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in a CME activity. The **owners** and **employees** of ineligible companies are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

There are three exceptions to this exclusion—employees of ineligible companies can participate as planners or faculty in these specific situations:

- When the content of the activity is not related to the business lines or products of their employer/company.
- When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, and they do not make care recommendations.
- When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

To assist all CME planners and contributors in identifying relevant relationships, ASBrS staff provides a sample list of typical relevant relationships and possible methods for mitigation—as well as examples of non-compliant actions. However, this list is not an exhaustive list of all scenarios. Participants are required to disclose all possible competing interests, both financial and non-financial, that could interfere with, or could reasonably be perceived as interfering with, their ability to provide objective and valuable contributions to the ASBrS CME activity.

All identified relevant relationships are mitigated prior to the education activity being delivered to learners per ACCME Standards. The inability to mitigate an identified relevant relationship results in the participant's withdrawal from participation in the CME activity.

A list of disclosures from all CME planners and contributors, as well as all potential and actual mitigation methods (including any instances of non-compliance), are documented and maintained by ASBrS staff. This list is made available to all CME activity planners.

The non-compliance process is initiated when an individual's (in a position to control educational content of the CME activity) *undisclosed* relationship(s) with an ineligible company is identified or reported during or after the CME activity. The Board of Directors, CME Committee, Ethics Committee, and applicable committee chair(s) will discuss the act of noncompliance and agree upon a resolution.

Oversight

The CME Committee and Ethics Committees ensure that there is no commercial bias or influence in ASBrS CME

activities. They work together to ensure proper conflict management. Members of these committees serve as additional oversight, participating and observing ASBrS CME activities to look for any evidence of bias and ensure compliance with the ASBrS policies.

Reporting Conflicts

Participants of any ASBrS CME activity may report any improprieties on the applicable evaluation form and to the CME and Ethics Committee at cme@breastsurgeons.org.

Please note we have advised speakers it is their responsibility to also disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The following individuals and groups have been involved in the planning, implementation, approval, and/or evaluation of this activity:

Faculty Name	NOTHING TO DISCLOSE	All Disclosed Relationship(s)	Faculty Relationship(s) Relevant to Course Participation/ Presentation - Yes/No	CME Committee Mitigation (All relevant relationships have been reviewed and mitigated by a designated CME Committee Official)
Deanna Attai, MD, FACS		<ul style="list-style-type: none"> Pfizer; Research Grant (3/2021-3/2022) 	No	
Tarah Ballinger, MD	X			
Mark Basik, MD		<ul style="list-style-type: none"> Astra Zeneca; Research 	No	
Richard Barth, Jr., MD, FACS		<ul style="list-style-type: none"> Cairnsurgical, Inc.; Chief Medical Officer 		
Vivian Bea, MD		<ul style="list-style-type: none"> Pfizer; Research Grant 	No	
Peter Beitsch, MD, FACS		<ul style="list-style-type: none"> Targeted Medical Education (TME); Owner InVita; Salary 	Yes	<p>All relationships are relevant Dr. Beitsch attested that: 1. The clinical recommendations are evidence-based and will be free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines)</p> <p>2. Discussions, teaching, and demonstrations will be fair, balanced, and unbiased.</p>
Sarah Blair, MD, FACS	X			
Gregory Boller, PhD	X			
Judy Boughey, MD		<ul style="list-style-type: none"> Lily; Research Support, Study PI SimBioSys; Consultant 	No	

Susan Boolbol, MD		<ul style="list-style-type: none"> Peace Medical Consulting; Consultant 	No	
David Brenin, MD, FACS		<ul style="list-style-type: none"> Theraclion; Researcher 		
Jennifer Brown	X			
Jeffrey Chakedis, MD, FACS	X			
Abhishek Chatterjee, MD, MBA, FACS		<ul style="list-style-type: none"> Biomup; Consultant, Speaker, Researcher 3MConsultant; Speaker; Researcher 	No	
Anna Chichura, MD		<ul style="list-style-type: none"> Hologic; Educational Support, Travel 	No	
Hiram Cody, III, MD, FACS	X			
Christopher Comstock, MD		<ul style="list-style-type: none"> Bracco Diagnostic Inc.; Speakers Bureau 	No	
Suzanne Coopey, MD, FACS	X			
Brian Czerniecki, MD, PhD		<ul style="list-style-type: none"> ImmunoRestoration; Intellectual Property 	No	
Amy Cyr, MD, FACS		<ul style="list-style-type: none"> Philips Ultrasound; Writer/Editor 		
Lucy De La Cruz, MD	X			
Emilia Diego, MD, FACS	X			
Jill Dietz, MD	X			
Souzan El-Eid, MD, FACS	X			
Leisha Elmore, MD, MPHS	X			
Betty Fan, DO, FACS	X			
Jennifer Farmer	X			
Deborah Farr, MD, FACS	X			
Oluwadamilola Fayanju, MD, MA, MPHS, FACS	X			
Sheldon Feldman, MD, FACS		<ul style="list-style-type: none"> Impedimed; Advisory Board 	No	
Richard Fine, MD, FACS		<ul style="list-style-type: none"> IceCure Medical; Advisor Hologic; Consultant, Advisor 	No	

Carla Fisher, MD MBA, FACS				
Armando Giuliano, MD, FACS, FRCSEd		<ul style="list-style-type: none"> Black Light Surgical Inc.; Consultant 	No	
Katherine Glover-Collins, MD, PhD	X			
Rachel Greenup, MD, MPH, FACS	X			
Linda Han, MD, FACS, FSSO		<ul style="list-style-type: none"> Hologic; Consultant Cardinal Health; Speaker Sonera Solutions; Advisor Vibronix; Advisor 	No	
Aladdin Hassanein, MD, MMSc, FACS	X			
Ronda Henry-Tillman, MD	X			
Dennis Holmes, MD, FACS	X			
James Jakub, MD, FACS		<ul style="list-style-type: none"> Sorrento Therapeutics; Royalties Novartis Melanoma Oncology; Advisory Board (2020) 	No	
Nathalie Johnson, MD, FACS	X			
Kathie-Ann Joseph, MD, MPH, FACS	X			
Manish Karamchandani, MD	X			
Kaitlyn Kennard, MD	X			
Brigid Killelea, MD, MPH, FACS		<ul style="list-style-type: none"> CytoVeris; Consultant UptoDate; Contributor 	No	
V. Suzanne Klimberg, MD, PhD, MSHCT, FACS	X			
Katherine Kopkash, MD, FACS		<ul style="list-style-type: none"> Intuitive Surgical; Investigator 		
Henry Kuerer, MD, PhD, FACS	X			
Christine Laronga, MD, FACS	X			
Daniel Leff, FRCS, MS (Hons), PhD		<ul style="list-style-type: none"> CMR Surgical; Advisor 	No	
Kandice Ludwig, MD, FACS	X			
Sharon Lum, MD, FACS	X			

Jennifer Matro, MD		<ul style="list-style-type: none"> Pfizer; Speaker OncLive; Speaker 	No	
Julie Margenthaler, MD, FACS	X		No	
Jane Mendez, MD, FACS	X			
Katrina Mitchell, MD, FACS	X			
Giacomo Montagna, MD, MPH	X			
Tracy-Ann Moo, MD, FACS	X			
Meena Moran, MD	X			
Terence Myckatyn, BSc (Hon), MD		<ul style="list-style-type: none"> RTI Surgical; Royalties, Research Grant, Advisory Board Fees Sientra; Research 	Yes (RTI Surgical)	Dr. Myckatyn's relationship with RTI surgical is relevant to his presentation. The educational content has been peer reviewed; clinical recommendations will be free of commercial bias and the content of the presentation will not promote commercial material.
Faina Nakhlis, MD, FACS	X			
Asha Nanda	X			
Kyra Nicholson, MD	X			
Toan Nguyen, MD, FACS	X			
Jennifer O'Neill, MD, FACS	X			
Javier Orozco, MD, MSc	X			
Helen Pass, MD, FACS		<ul style="list-style-type: none"> Genomic Health; Honorarium; Speaker's Bureau Genentech; Honorarium; Speaker 	No	
Catherine Pesce, MD, FACS	X			
Hanna Peifer	X			
Christine Pestana, MD	X			

Melissa Pilewskie, MD, FACS	X			
Omar Qutob, MD	X			
Roshni Rao, MD	X			
Thomas Robbins	X			
Gonzalo Ziegler Rodriguez, MD	X			
Terry Sarantou, MD, FACS	X			
Abida Sattar, MD, FACS	X			
Kathryn Schmitz, PhD, MPH	X			
Theresa Schwartz, MD, MS, FACS	X			
Aanshu Shah, MD	X			
Elizabeth Shaughnessy, MD, PhD, FACS, FSSO		<ul style="list-style-type: none"> Impedimed - Advisory Board 	No	
Shayna Showalter, MD, FACS	X			
Puneet Singh, MD	X			
Howard Snider, Jr., MD, FACS	X			
Atilla Soran, MD, MPH, FNBC, FACS		<ul style="list-style-type: none"> Impedimed; Advisor 	No	
Preeti Subhedar, MD, FACS	X			
Jeffrey Sugandi, MD	X			
Walton Taylor, MD, FACS		<ul style="list-style-type: none"> Impedimed; Consultant iCad; Consultant Targeted Medical Education (TME); Consultant 	No	
Mediget Teshome, MD, MPH, FACS		<ul style="list-style-type: none"> Allergan; Consultant RTI Surgical; Consultant Mentor; Grant Funding NC8; Consultant 	No	
Marissa Tenenbaum, MD				
Alyssa Throckmorton, MD, FACS		<ul style="list-style-type: none"> Targeted Medical Education (TME); Honorarium, Travel 	No	

		Expenses; Advisory Board		
Todd Tuttle, MD, FACS	X			
Stacy Ugras, MD, FACS	X			
Stephanie Valente, DO, FACS		<ul style="list-style-type: none"> • Impedimed; Speaker, Advisory Board • Merit Medical; Speaker, Advisory Board • Axogen; Advisory Board • Pacira; Speaker, Consultant • Guard Medical; Advisor 	No	
Sabrina Wang	X			
Anna Weiss, MD, FACS		<ul style="list-style-type: none"> • Myriad Labs Inc.; Research 	No	
Lee Wilke, MD, FACS		<ul style="list-style-type: none"> • Elucent Medical; Founder, Minority Stock Owner (less than 5%) • Perimeter Medical; Principal Investigator 	No	
Shawna Willey, MD, FACS		<ul style="list-style-type: none"> • Genentech; Honorarium; Speaker • Pacira; Honorarium; Speaker • Hologic; Honorarium; Advisory Board • Exact Sciences; Honorarium; Advisory Board • TransMed7; Honorarium, Stock; Advisory Board Investor • Stryker; Advisory Board 	Yes	<p>All relationships are relevant. Dr. Willey attested that: 1. The clinical recommendations are evidence-based and will be free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines)</p> <p>2. Discussions, teaching, and demonstrations will be fair, balanced, and unbiased.</p>

		<ul style="list-style-type: none"> Lumicell; Honorarium; DSMB Member 		
Rich Zellars, MD	X			
Chi Zhang, MD	X			

Board of Directors	NOTHING TO DISCLOSE	DISCLOSURE (All relationships with ineligible companies)		
NAME		All board members recused themselves from discussions and decisions where a conflict of interest could occur.		
		Company	Received	Role
Paul Baron, MD		Myriad Genetics (2018-present)	Honorarium	Speaker, consulting
		Targeted Medical Education (TME) (2021)	Honorarium	
Michael Berry, MD		TransMed7 (2019-present)	Stock	Stock
		Targeted Medical Education (TME) (2021)	Honorarium	
Susan Boolbol, MD		Peace Medical Consultants, LLC		
Judy Boughey, MD		Lily (2020-present)	Research Support	Study PI
		SimBioSys (2021)		
Jill Dietz, MD	X			
Nathalie Johnson, MD	X			
Eric Manahan, MD		Astrazeneca (2021)		
		Myriad Genetics (2021)		
		Targeted Medical Education (TME)	Honorarium	
Julie Margenthaler, MD	X			
Jane Mendez, MD	X			
Terry Sarantou, MD	X			
Shawna Willey, MD		Genentech (2017-present)	Honorarium	Speaker
		TME (2021)	Honorarium	
		Pacira (2021 - present)	Honorarium	Speaker

		Hologic (2019-present)	Honorarium	Advisory Board
		TransMed7 (2017-present)	Honorarium, Stock	Advisory Board, Investor
		Stryker (2019-present)		Advisory Board
		Lumicell (2017-present)	Honorarium	DSMB Member
		Medtronic (2017-present)	Honorarium	Speaker

CME Committee				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All relationships with ineligible companies)		
		Company	Received	Role
Joseph Contino, MD	X			
Lynn Dengel, MD	X			
Jillian Lloyd, MD	X			
Sarah McLaughlin, MD (Chair)	X			

Ethics Committee (Oversight)				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All relationships with ineligible companies) All committee members recused themselves from discussions and decisions where a conflict of interest could occur.		
		Company	Received	Role
Lisa Allen, MD	X			
Emily Bellavance, MD	X			
Tina Hieken, MD		Genentech	Research Funding to Institution	
		SkylineDx	Research Funding to Institution	
David Kaufman, MD	X			
Cindy Matsen, MD	X			
Toan Nguyen, MD (Chair)		Targeted Medical Education (TME)		Consultant
Steven Nagel, MD	X			
Caitlin Patten, MD	X			

Lauren Pomerence, MD	X			
Paige Teller, MD	X			
Sara Tevis, MD	X			
Jennifer Tseng, MD	X			

ASBrS Staff				
NAME	NOTHING TO DISCLOSE	DISCLOSURE (All relationships with ineligible companies)		
		Company	Received	Role
Marta Boyer, Director, Strategic Partnerships	X			
Erica J. Holland, Executive Director	X			
Christina Lucara, Meetings and Education Manager	X			
Tekoah White, CME Specialist	X			